Evidence map›Paper›PMID 42238573›Full record

ArticleFrontiers in immunology2026

CDK4/6 inhibition with dual immunotherapy in chemorefractory SMARCA4-deficient undifferentiated tumor: a case report.

Ünal Metin Tokat, Şevval Nur Bilgiç, Ashkan Adibi, Esranur Aydın, Onur Tutar, Hilal Cansız, Ali Yılmaz Altay, Nalan Akgul Babacan, Eylül Özgü, Alina Melisa Manea and 1 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Ünal Metin TokatPrecision Oncology Center, Medicana Health Group, Istanbul, Türkiye.
Şevval Nur BilgiçPrecision Oncology Center, Medicana Health Group, Istanbul, Türkiye.
Ashkan AdibiPrecision Oncology Center, Medicana Health Group, Istanbul, Türkiye.
Esranur AydınPrecision Oncology Center, Medicana Health Group, Istanbul, Türkiye.
Onur TutarDepartment of Internal Medicine, Cerrahpasa Faculty of Medicine, Istanbul University, Istanbul, Türkiye.
Hilal CansızEar Nose and Throat Clinic, Istanbul Haseki Training and Research Hospital, Sultangazi, Istanbul, Türkiye.
Ali Yılmaz AltayDepartment of Medical Pathology, Department of Surgical Medical Sciences, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Türkiye.
Nalan Akgul BabacanPrecision Oncology Center, Medicana Health Group, Istanbul, Türkiye.
Eylül ÖzgüPrecision Oncology Center, Medicana Health Group, Istanbul, Türkiye.
Alina Melisa ManeaPrecision Oncology Center, Medicana Health Group, Istanbul, Türkiye.
Mutlu DemirayPrecision Oncology Center, Medicana Health Group, Istanbul, Türkiye.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Thoracic SMARCA4-deficient undifferentiated tumors (SMARCA4-UT) are rare malignancies characterized by resistance to chemotherapy and poor clinical outcomes. While immunotherapy have shown promise, especially in the first-line treatment, effective therapeutic strategies for patients with PD-L1-negative tumors and complex genomic profiles remain undefined. We report a case of chemorefractory SMARCA4-UT in a patient presenting with cervical mass. CGP revealed pathogenic

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6DNA HelicasesNuclear ProteinsTranscription FactorsDrug Resistance, NeoplasmFemaleHumansImmunotherapyMutationPiperazinesPyridinesCDK4 protein, humanCDK6 protein, humanCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6DNA HelicasesNuclear ProteinspalbociclibPiperazinesPyridinesSMARCA4 protein, humanTranscription Factorscase reportCDK4/6 inhibitorimmunotherapyipilimumabpalbociclibpembrolizumabprecision oncologyThoracic SMARCA4-deficient undifferentiated tumor (SMARCA4-UT)

Identifiers

PMID42238573
PMCPMC13226164

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.